Eva S.
- Country
- Germany
- Department
- Klinik Nephrologie und Intensivmedizin
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Efgartigimod Alfa SC in Antibody-Mediated Rejection in Kidney Transplant Recipients
Data & Insights
Has run more than one trial at 210 of 628 partner sites.
Specializations
Infectious Diseases
This investigator specializes in the study of SARS-CoV-2 infection and its therapeutic management, with particular emphasis on treatment options for non-hospitalized patients.
- COVID-19 outpatient care
- Antiviral therapeutics
- Respiratory infections
The research focus includes evaluation of novel therapeutic approaches for patients at high risk of severe illness.
Clinical Therapeutics
The investigator concentrates on studying antiviral treatments in community settings, specifically examining their efficacy in preventing disease progression.
- Drug efficacy assessment
- Treatment safety profiles
- Patient risk stratification
Areas of interest include monitoring clinical outcomes and therapeutic responses in high-risk populations.
Disease Prevention
Research activities focus on preventive interventions aimed at reducing hospitalization rates and severe outcomes in viral infections.
- Early intervention strategies
- Outpatient management
- Medical attendance patterns
The investigator examines approaches to prevent disease progression in vulnerable populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.